| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03399435 2016-003958-33 Details | 2018-10-11 Interventional | 1 | 242 | Bupivacaine Epinephrine Epinephryl bora… Neosaxitoxin Racepinephrine Analgesia Anesthesia Anesthesia, Loc… | The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained
efficacy data. The decision is not related to any safety concern. - | |||
| NCT02831387 Details | 2018-10-11 Interventional | 2 | 47 | Ophthalmic Solu… Pharmaceutical … Dry Eye Syndrom… Eye Diseases Keratoconjuncti… Dry Eye Disease | - - | |||
| NCT02780700 Details | 2018-10-11 Interventional | 2 | 1 | Capecitabine Nintedanib Colorectal Neop… | Substance discontinued Trial was terminated prematurely because it was determined that nintedanib monotherapy demonstrated lack of efficacy in this indication in pivotal Phase III trial (LUME-Colon 1) that was ongoing at the time of the initiation of this trial. | |||
| NCT02055924 Details | 2018-10-11 Interventional | 1 | 85 | Ibrutinib Lymphoma Lymphoma, B-Cel… B-cell Lymphoma | ANSM decision due to veino occlusive disease (security alert) - | |||
| NCT01820325 2012-005541-21 Details | 2018-10-11 Interventional | 1 | 6 | Carboplatin Paclitaxel Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Due to DLTs/AEs safety profile considered challenging. - | |||
| NCT00090779 Details | 2018-10-11 Interventional | 2 | [2 Refs] | 130 | Emtricitabine Emtricitabine, … Lopinavir Ritonavir Tenofovir HIV Infections | The DSMB concluded that the findings regarding the primary analysis would persist and that no
additional study goals would be achieved by continuing the study. - | ||
| NCT03698045 Details | 2018-10-10 Interventional | 1 | 0 | Ophthalmic Solu… Conjunctivitis Conjunctivitis,… | the clinical study was canceled by the sponsor due to logistics and programming - | |||
| NCT03496519 Details | 2018-10-09 Interventional | 1 | 0 | Antibodies, Mon… Durvalumab Trabectedin Neoplasms Solid Tumor, Ad… | Contract Issues - | |||
| NCT03340558 Details | 2018-10-09 Interventional | 2 | 0 | Atezolizumab Colorectal Neop… Metastatic Colo… | Negative results in a similar study - | |||
| NCT03310567 Details | 2018-10-09 Interventional | 2 | 0 | Pembrolizumab Carcinoma Endometrial Neo… Recurrence Recurrent/ Meta… | Sponsors pulled out of the study - | |||
| NCT02434549 Details | 2018-10-09 Interventional | 2 | 16 | abobotulinumtox… Cerebral Palsy Muscle Spastici… Paralysis Cerebral Palsy,… Pain | Based on efficacy results from interim analysis - | |||
| NCT01667107 2012-003140-68 Details | 2018-10-09 Interventional | 4 | 26 | Posaconazole Mycoses Fungal Infectio… | Study terminated due to an unfavorable risk-benefit analysis - | |||
| NCT02565147 2012-002314-39 Details | 2018-10-05 Interventional | 3 | 78 | Bivalirudin Heparin Infarction Myocardial Infa… Acute Myocardia… | Futility at the interim analysis. Since the measured difference in infarct size at Day 5 (by CMR) was <18%, the study was terminated for futility at the interim analysis as pre-defined in the protocol. | |||
| NCT02794714 Details | 2018-10-04 Interventional | 4 | 0 | Rocuronium Neuromuscular B… | unresolved budget issues - | |||
| NCT00975104 Details | 2018-10-04 Interventional | 2 | 0 | Immunoglobulin … Age-associated … | Amgen has chosen at this time not to continue with AMG 745 study 20080733 - | |||
| NCT02960503 Details | 2018-10-02 Interventional | 1/2 | 0 | Azithromycin Anemia, Sickle … Sickle Cell Dis… | Key personnel moved to new location. Therefore, we had insufficient resources to initiate the
trial. - | |||
| NCT02580708 Details | 2018-10-02 Interventional | 1/2 | 7 | Trametinib Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Discontinued development of rociletinib in NSCLC. Stopped enrollment of new patients into all
studies involving rociletinib. - | |||
| NCT01657240 Details | 2018-10-02 Interventional | 3 | 0 | Olopatadine Hyd… Ophthalmic Solu… Pharmaceutical … Conjunctivitis Conjunctivitis,… Allergic Conjun… | Formula Reformulation - | |||
| NCT01541904 Details | 2018-10-02 Interventional | 2 | 0 | Ophthalmic Solu… Pharmaceutical … Conjunctivitis Conjunctivitis,… Ocular Allergy Ocular Itching Perennial Aller… Seasonal Allerg… | Reformulation - | |||
| NCT02769702 Details | 2018-10-01 Interventional | 4 | 2 | Adrenocorticotr… Iridocyclitis Uveitis Uveitis, Anteri… | - This study was prematurely terminated, only 2 participants enrolled. Although results are reported they should be interpreted with caution due to small sample size. |